Navigation Links
Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
Date:9/25/2011

EAST HANOVER, N.J., Sept. 25, 2011 /PRNewswire/ -- Novartis announced new data today from the pivotal Phase III IMPRES clinical trial showing that the investigational therapy QTI571 (imatinib) significantly improved exercise capacity in patients with pulmonary arterial hypertension (PAH) after 24 weeks compared with placebo(1). Evidence indicates that QTI571 targets an underlying cause of PAH by counteracting uncontrolled growth of arterial smooth muscle cells(2).

The IMPRES study met its primary endpoint by demonstrating a significant improvement in the six-minute walk distance (6MWD) test in patients with elevated pulmonary vascular resistance (PVR) despite treatment with two or more specific PAH vasodilator therapies(1). The 6MWD is a predictor of survival in PAH patients(5,6), and is commonly used to assess exercise capacity in PAH clinical trials(7,8,9). In the study, patients treated with QTI571 increased their mean 6MWD by 31.8 meters compared with placebo (p=0.002)(1).

The study's secondary endpoints showed that QTI571 produced statistically significant improvements compared to placebo in pulmonary arterial pressure, cardiac output and pulmonary vascular resistance (all p<0.001)(1), but not in time to clinical worsening (i.e. death, hospitalization due to PAH, worsening of functional class, or >15% drop in 6MWD) (p=0.563)(1).

"These results are impressive as they were achieved in patients who were already receiving two or more established PAH drugs," said Marius Hoeper MD, Associate Professor, Department of Respiratory Medicine at Hannover Medical School, Germany and principal investigator of the IMPRES study. The data were presented for the first time at the European Respiratory Society (ERS) Annual Congress in Amsterdam, The Netherlands.

PAH is a debilitating disease of the heart and lungs that is characterized by a marked and sustained elevation in pulmonary artery pressure. The disease is chroni
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015  MEI Pharma, Inc. (Nasdaq: ... development of novel therapies for cancer, announced today that ... will present at the Bank of America Merrill Lynch 2015 ... a.m. Pacific time from the Encore at the Wynn in ... the presentation can be accessed at www.meipharma.com . A ...
(Date:5/6/2015)... , May 6, 2015  TriStar Wellness Solutions(R), ... that targets opportunities in the advanced wound care ... Oregon based wholly owned independent subsidiary ... funding from the National Institutes of Health (NIH) ... that is able to be delivered by a ...
(Date:5/6/2015)... , May 6, 2015  Genomic Health, Inc. (Nasdaq: ... , Chairman of the Board, Chief Executive Officer & ... Lynch 2015 Healthcare Conference in Las Vegas ... Pacific Time (PT). To access the live ... the  Investor Relations  section of the company,s web site ...
Breaking Medicine Technology:MEI Pharma to Present at Bank of America Merrill Lynch Health Care Conference 2Collaboration Between HemCon and OHSU is Awarded Additional NIH Grant with Total Value of $1.1M for the Development of a Transurethral Hemostatic Device 2Collaboration Between HemCon and OHSU is Awarded Additional NIH Grant with Total Value of $1.1M for the Development of a Transurethral Hemostatic Device 3Collaboration Between HemCon and OHSU is Awarded Additional NIH Grant with Total Value of $1.1M for the Development of a Transurethral Hemostatic Device 4Collaboration Between HemCon and OHSU is Awarded Additional NIH Grant with Total Value of $1.1M for the Development of a Transurethral Hemostatic Device 5Genomic Health to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference 2Genomic Health to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference 3
... , , ROSH ... of innovative solutions for the advanced chronic,wound management market, ... Food and Drug Administration (FDA) to market its new,SilverStream(TM) ... Over-the-Counter version of the SilverStream product. , ...
... , , , , ... NXTM ), a leading manufacturer of innovative dialysis products, ... and their partners will be embarking on a week-long, conventional ... The cruise, dubbed the "2010 Freedom Cruise: We,re Taking Home ...
Cached Medicine Technology:EnzySurge Receives FDA Approval for SilverStream(TM) Innovative Wound Management Solution 2Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 2Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 3Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 4
(Date:5/6/2015)... Topical BioMedics, Inc., announces its May Pain Management Webinar will ... streamed live and then archived and accessible on demand 24/7. ... clicking on the following link: http://bit.ly/PMW_FIBRO . ... the webinar, and questions may also be submitted in advance ... the May webinar is “What You need to Know about ...
(Date:5/6/2015)... Cloud security companies Sookasa Inc ... partnership to help small-to-medium businesses secure their sensitive data ... are teaming up to transition SafeMonk customers to Sookasa’s ... to welcome SafeMonk users to the Sookasa family, and ... SafeMonk, the global powerhouse SafeNet (now Gemalto IDSS), are ...
(Date:5/6/2015)... Arizona (PRWEB) May 06, 2015 ... IMMEDIATE RELEASE , Med Ag Ventures, Inc. (MAV), ... manufacturing capacity of its Arizona based Phoenician Engineering ... grinders last September. MAV recently achieved profitability from ... network expanded from 100 at the end of ...
(Date:5/6/2015)... Hope For The Warriors® and American ... at the New York Athletic Club on April 21, ... The Warriors®, a national nonprofit dedicated to restoring a ... hope for our service members and our military families. ... local and nationwide military families. The Barry Fixler Foundation/Semper ...
(Date:5/6/2015)... 06, 2015 The Jefferson Awards ... to activating and celebrating public service, announced today ... Health, as an Outstanding Employee Volunteer Organization. Champions ... Awards Foundation, are dedicated to building a culture ... decade, Highmark Health has recognized employees who volunteer ...
Breaking Medicine News(10 mins):Health News:Topical BioMedics Hosts May Pain Management Webinar “What You need to Know about Fibromyalgia” 2Health News:Topical BioMedics Hosts May Pain Management Webinar “What You need to Know about Fibromyalgia” 3Health News:Topical BioMedics Hosts May Pain Management Webinar “What You need to Know about Fibromyalgia” 4Health News:Topical BioMedics Hosts May Pain Management Webinar “What You need to Know about Fibromyalgia” 5Health News:Sookasa Grows Globally With SafeMonk Partnership 2Health News:Sookasa Grows Globally With SafeMonk Partnership 3Health News:Cannibus Industry Start-Up Reaches Profitability While Expanding Its Proprietary Ancillary Medical Marijuana Product IP Portfolio 2Health News:4th Annual Casino Night Draws Support for Military Families in New York City Region 2Health News:The Jefferson Awards Foundation Honors Highmark Health 2Health News:The Jefferson Awards Foundation Honors Highmark Health 3Health News:The Jefferson Awards Foundation Honors Highmark Health 4
... rapidly changing the clinical practice of oncology. As scientists ... development of new tools capable of multiple, inexpensive biomarker ... essential to the success of genetically informed and personalized ... now developed a microfluidic image cytometry (MIC) platform that ...
... a single rock being overturned or an entire mountaintop ... processes, and vice versa. Ecological scientists will discuss findings ... growth to the diversity of insect species on green ... buildingsat the Ecological Society of America,s 95th Annual Meeting ...
... , , , , , ... , , AUDIO: ... School of Medicine... , Click here for more information. ... , , , , , ...
... HealthDay Reporter , MONDAY, August 2 (HealthDay News) -- ... than normal are at greater risk of developing artery-clogging ... of the arteries leading to heart disease, a new ... common assumption that modestly high cholesterol levels are nothing ...
... August 2, 2010 From the many images sent home ... viewed the plight of their country,s combat-weary veterans as stark ... But recent research at Washington State University (WSU) suggests that, ... often sets the trajectory of the balance of their lives. ...
... PICK: Boosting the efficacy of anticancer vaccines ... anticancer vaccines, which are designed to boost the patient,s ... example, the viruses used to deliver the tumor protein ... the patient,s immune system, inducing neutralizing and suppressive responses. ...
Cached Medicine News:Health News:New diagnostic chip able to generate single-cell molecular 'fingerprints' for brain tumors 2Health News:New diagnostic chip able to generate single-cell molecular 'fingerprints' for brain tumors 3Health News:Scientists unravel human-ecosystem interactions 2Health News:Scientists unravel human-ecosystem interactions 3Health News:Scientists unravel human-ecosystem interactions 4Health News:Colitis patients diagnosed later in life tend to have better disease outcomes 2Health News:Colitis patients diagnosed later in life tend to have better disease outcomes 3Health News:Colitis patients diagnosed later in life tend to have better disease outcomes 4Health News:High Cholesterol in Youth Boosts Heart Risk In Middle Age 2Health News:High Cholesterol in Youth Boosts Heart Risk In Middle Age 3Health News:High Cholesterol in Youth Boosts Heart Risk In Middle Age 4Health News:Sociologist finds combat veterans face more lifelong socioeconomic challenges 2Health News:JCI online early table of contents: August 2, 2010 2Health News:JCI online early table of contents: August 2, 2010 3Health News:JCI online early table of contents: August 2, 2010 4Health News:JCI online early table of contents: August 2, 2010 5Health News:JCI online early table of contents: August 2, 2010 6
... refrigerator is specially designed ... blood in standard 500ml ... Standard AS3864 1997. Quiet ... utilising CFC Free refrigerant ...
TBR-720-2-GD is large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standard AS38...
DSL-10-49300 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in saliva. This assay requires no sample extraction or pretreat...
... circulating testosterone exists as unbound or free ... to SHBG with high affinity [1], while ... Both the albumin-bound and free fractions may ... testosterone action. Measurement of the free or ...
Medicine Products: